Treatment of mood disorders

Nature Neuroscience

Volumn 5, Issue 11s, 2002, Pages 1068-1070

  Nemeroff, Charles B ^a   Owens, Michael J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APREPITANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; DULOXETINE; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; GEPIRONE; IPSAPIRONE; LITHIUM; MIFEPRISTONE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PINDOLOL; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE;

CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LIVER TOXICITY; MOOD DISORDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; REVIEW; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; DRUG DESIGN; HUMANS; RECEPTORS, NEUROTRANSMITTER; SYNAPTIC TRANSMISSION;

EID: 0036830579     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn943     Document Type: Article

References (27)

1. Kessler, R. C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. Gen. Psychiatry 51, 8-19 (1994).
2. Blazer, D. G. et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 151, 979-986 (1994).
3. Murray, C. J. L. & Lopez, A. D. (eds.) The Global Burden of Disease (Harvard Univ. Press, Boston, 1996).
4. Klerman, G. L. et al. Birth-cohort trends in rates of major depressive disorder among relatives of patients with affective disorder. Arch. Gen. Psychiatry 42, 689-693 (1985).
5. Musselman, D. L., Evans, D. L. & Nemeroff, C. B. The relationship of depression to cardiovascular disease: diagnosis, biology and treatment. Arch. Gen. Psychiatry 55, 580-592 (1998).
6. Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression following myocardial infarction: impact on 6-month survival. JAMA 270, 1819-1825 (1993).
7. Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression and 18-month prognosis after myocardial infarction. Circulation 91, 999-1005 (1995).
8. Sanders, A. R., Detera-Wadleigh, S. D. & Gershon, E. S. in Neurobiology of Mental Illness (eds. Charney, D. S., Nestler, E. J. & Bunne, y B. S.) 299-316 (Oxford Univ. Press, New York, 1999).
9. Duman, R. S., Heninger, G. R. & Nestler, E. J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597-606 (1997).
10. Thome, J. et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20, 4030-4036 (2000).
11. Entsuah, A. R., Huang, H. & Thase, M. E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62, 869-877 (2001).
12. Thase, M. E., Entsuah, A. R. & Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241 (2001).
13. Owens, M. J. & Nemeroff, C. B. The serotonin transporter and depression. Depress. Anxiety 8(S1), 5-12 (1998).
14. Ressler, K. J. & Nemeroff, C. B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 46, 1219-1233 (1999).
15. Meyer, J. H. et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 12, 4121-4125 (2001).
16. Anderson, I. M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disorders 58, 19-36 (2000).
17. Gilmor, M. L., Owens, M. J. & Nemeroff, C.B. Inhibition of norepinephrine uptake in patients with major depression treated with the selective serotonin reuptake inhibitor paroxetine. Am. J. Psychiatry (in press).
18. Owens, M. J. et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305-1322 (1997).
19. Blier, B. Pharmacology of rapid-onset antidepressant treatment strategies.J. Clin. Psychiatry 62(S15), 12-17 (2001).
20. Rabiner, E. A. et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry 158, 2080-2082 (2001).
21. Owens, M. J. & Nemeroff, C. B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43, 425-473 (1991).
22. Reul, J. M. & Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2, 23-33 (2002).
23. Zobel, A. W. et al. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatry Res. 34, 171-181 (2000).
24. Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B. & Schatzberg, A. F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21, 516-521 (2001).
25. Kramer, M. S. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645 (1998).
26. Stout, S. C., Owens, M. J. & Nemeroff, C. B. Neurokinin1receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. 41, 877-906 (2001).
27. 11C]DASB PET imaging study. Am. J. Psychiatry 158, 1843-1849 (2001).